Ad is loading...
RCUS
Price
$14.70
Change
+$0.42 (+2.94%)
Updated
Nov 22 closing price
88 days until earnings call
RIGL
Price
$26.04
Change
+$1.00 (+3.99%)
Updated
Nov 22 closing price
Ad is loading...

RCUS vs RIGL

Header iconRCUS vs RIGL Comparison
Open Charts RCUS vs RIGLBanner chart's image
Arcus Biosciences
Price$14.70
Change+$0.42 (+2.94%)
Volume$534.48K
CapitalizationN/A
Rigel Pharmaceuticals
Price$26.04
Change+$1.00 (+3.99%)
Volume$129.27K
CapitalizationN/A
RCUS vs RIGL Comparison Chart
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
RCUS vs. RIGL commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a Hold and RIGL is a Buy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (RCUS: $14.70 vs. RIGL: $26.04)
Brand notoriety: RCUS and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 70% vs. RIGL: 56%
Market capitalization -- RCUS: $1.35B vs. RIGL: $458.7M
RCUS [@Biotechnology] is valued at $1.35B. RIGL’s [@Biotechnology] market capitalization is $458.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, RIGL is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).

  • RCUS’s TA Score: 4 bullish, 6 bearish.
  • RIGL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than RCUS.

Price Growth

RCUS (@Biotechnology) experienced а -6.37% price change this week, while RIGL (@Biotechnology) price change was +8.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

RCUS is expected to report earnings on Feb 19, 2025.

RIGL is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.35B) has a higher market cap than RIGL($459M). RIGL YTD gains are higher at: 79.586 vs. RCUS (-23.037). RIGL has higher annual earnings (EBITDA): 13.7M vs. RCUS (-257M). RCUS has more cash in the bank: 1.09B vs. RIGL (61.1M). RCUS (58M) and RIGL (60.2M) have identical debt. RCUS has higher revenues than RIGL: RCUS (263M) vs RIGL (157M).
RCUSRIGLRCUS / RIGL
Capitalization1.35B459M293%
EBITDA-257M13.7M-1,876%
Gain YTD-23.03779.586-29%
P/E RatioN/A96.44-
Revenue263M157M168%
Total Cash1.09B61.1M1,782%
Total Debt58M60.2M96%
FUNDAMENTALS RATINGS
RCUS vs RIGL: Fundamental Ratings
RCUS
RIGL
OUTLOOK RATING
1..100
7328
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
7783
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6434
P/E GROWTH RATING
1..100
9971
SEASONALITY SCORE
1..100
8513

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (57) in the Pharmaceuticals Major industry is in the same range as RIGL (89) in the Biotechnology industry. This means that RCUS’s stock grew similarly to RIGL’s over the last 12 months.

RCUS's Profit vs Risk Rating (77) in the Pharmaceuticals Major industry is in the same range as RIGL (83) in the Biotechnology industry. This means that RCUS’s stock grew similarly to RIGL’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as RIGL (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Price Growth Rating (34) in the Biotechnology industry is in the same range as RCUS (64) in the Pharmaceuticals Major industry. This means that RIGL’s stock grew similarly to RCUS’s over the last 12 months.

RIGL's P/E Growth Rating (71) in the Biotechnology industry is in the same range as RCUS (99) in the Pharmaceuticals Major industry. This means that RIGL’s stock grew similarly to RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSRIGL
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Ad is loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRMIX38.240.42
+1.11%
T. Rowe Price Mid-Cap Value I
THCRX31.790.28
+0.89%
Thornburg Small/Mid Cap Growth R3
SLCAX17.290.08
+0.46%
SEI Large Cap A (SIIT)
AIIEX23.210.09
+0.39%
Invesco EQV International Equity A
GFVIX17.43N/A
N/A
Goldman Sachs Focused Value Inv

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+2.94%
ACLX - RCUS
47%
Loosely correlated
+3.69%
DNLI - RCUS
46%
Loosely correlated
+1.94%
PRME - RCUS
46%
Loosely correlated
+7.74%
ALEC - RCUS
45%
Loosely correlated
+4.79%
ABCL - RCUS
45%
Loosely correlated
+1.47%
More